Legal & General Group Plc Reduces Stock Position in IDEXX Laboratories, Inc. $IDXX

Legal & General Group Plc cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 670,614 shares of the company’s stock after selling 4,921 shares during the quarter. Legal & General Group Plc’s holdings in IDEXX Laboratories were worth $453,690,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Greykasell Wealth Strategies Inc. purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $35,000. Finally, WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $559.37 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98. The firm has a market capitalization of $44.12 billion, a P/E ratio of 41.19, a P/E/G ratio of 3.25 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The business has a 50 day simple moving average of $566.27 and a 200 day simple moving average of $640.99.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm posted $2.91 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president owned 19,899 shares in the company, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 27,777 shares of company stock valued at $18,235,113 in the last 90 days. Insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on IDXX shares. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.